Valuation: Beta Bionics, Inc.

Market Cap 751M 657M 606M 557M 1.06B 72.29B 1.07B 7.23B 2.84B 35.33B 2.82B 2.76B 122B P/E 2026 *
-7.56x
P/E 2027 * -7.57x
Enterprise Value 577M 504M 465M 427M 810M 55.47B 824M 5.55B 2.18B 27.11B 2.16B 2.12B 93.45B EV / Sales 2026 *
4.32x
EV / Sales 2027 * 3.62x
Free-Float
98.91%
Yield 2026 *
-
Yield 2027 * -
1 day+3.29%
1 week+7.24%
Current month+12.44%
1 month+26.31%
3 months+44.66%
6 months-4.76%
Current year-42.17%
1 week 15.92
Extreme 15.92
17.87
1 month 13.02
Extreme 13.02
17.87
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap.
06-29Fiscal year

Chief Financial Officer

14,688 0.0330%
06-29Fiscal year

Chief Financial Officer

14,688 0.0330%
06-24Sell

Executive/Senior Manager

-1,258 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
+2.97%+7.24%+39.18% - 751M
+0.98%+3.32%+30.23%+3.22% 199B
+1.81%+4.47%+5.92%-13.89% 142B
+3.20%-2.40%-21.64%+13.52% 138B
+3.79%-0.78%-56.74%-15.15% 63.97B
+2.07%-2.20%+17.31%-3.59% 50.25B
+0.83%+1.98%-23.96%-31.92% 44.33B
-0.24%+1.08%+19.05%+14.19% 38.05B
+0.55%+0.50%+30.89%+40.46% 36.81B
+2.36%-0.28%-14.49%-20.53% 28.75B
Average +1.91%-0.03%+2.57%-1.52% 74.17B
Weighted average by Cap. +1.87%+0.19%+2.06%-0.81%

Financials

2026 *2027 *
Net sales 133M 117M 108M 98.84M 187M 12.83B 190M 1.28B 504M 6.27B 501M 490M 21.61B 180M 157M 145M 133M 252M 17.28B 257M 1.73B 678M 8.44B 674M 659M 29.11B
Net income -99.93M -87.37M -80.6M -74.09M -140M -9.62B -143M -962M -378M -4.7B -375M -367M -16.2B -99.35M -86.86M -80.13M -73.66M -140M -9.56B -142M -957M -375M -4.67B -373M -365M -16.1B
Net Debt -175M -153M -141M -130M -246M -16.82B -250M -1.68B -660M -8.22B -656M -642M -28.34B -101M -88.4M -81.55M -74.96M -142M -9.73B -144M -974M -382M -4.76B -380M -371M -16.39B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
16/07/26 $17.54 +4.03% 81,137
15/07/26 $16.86 0.00% 1,746,679
14/07/26 $16.86 -0.53% 1,476,016
13/07/26 $16.95 -0.47% 1,015,548
10/07/26 $17.03 +3.65% 1,060,536
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
16.86USD
Average target price
19.80USD
Spread / Average Target
+17.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock